A Phase I, Open-label Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of EMD525797 After Single Dose and Repeated Dosing at Different Dose Levels in Japanese Patients With Advanced or Metastatic Solid Tumors and Progressive Diseases Following Prior Chemotherapy.
Phase of Trial: Phase I
Latest Information Update: 25 May 2016
At a glance
- Drugs Abituzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck KGaA
- 13 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Apr 2011 New trial record